Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1

British Journal of Cancer

Volumn 110, Issue 6, 2014, Pages 1481-1487

  Akashi, Y ^a   Oda, T ^a   Ohara, Y ^a   Miyamoto, R ^a   Kurokawa, T ^a   Hashimoto, S ^a   Enomoto, T ^a   Yamada, K ^a   Satake, M ^b   Ohkohchi, N ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

gemcitabine; iRGD peptide; neuropilin 1; pancreatic cancer; tumour graft

Indexed keywords

GEMCITABINE; INTERNALISED RGD PEPTIDE; NEUROPILIN 1; NEUROPILIN 1 RECEPTOR; PEPTIDE; RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRAFT; CANCER SURGERY; CLINICAL ARTICLE; DRUG ACCUMULATION; DRUG PENETRATION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; NEUROPILIN-1; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896488811     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.49     Document Type: Article

References (23)

1. Akashi Y, Oda T, Ohara Y, Miyamoto R, Hashimoto S, Enomoto T, Yamada K, Kobayashi A, Fukunaga K, Ohkochi N (2013) Histological advantages of the tumor graft, a murine model involving transplantation of human pancreatic cancer tissue fragments. Pancreas 42: 1275-1282.
2. Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413.
3. Dong X, Guan J, English JC, Flint J, Yee J, Evans K, Murray N, Macaulay C, Ng RT, Gout PW, Lam WL, Laskin J, Ling V, Lam S, Wang Y (2010) Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res 16: 1442-1451.
4. Fukahi K, Fukasawa M, Neufeld G, Itakura J, Korc M (2004) Aberrant expression of neuropilin-1 and-2 in human pancreatic cancer cells. Clin Cancer Res 10: 581-590.
5. Hansel DE, Wilentz RE, Yeo CJ, Schulick RD, Montgomery E, Maitra A (2004) Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. Am J Surg Pathol 28: 347-356.
6. Heldin CH, Rubin K, Pietras K, Ostman A (2004) High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 4: 806-813.
7. Hidalgo M, Brunckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D (2011) A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 10: 1311-1316.
8. Jain RK (1999) Transport of molecules, particles, and cell in solid tumors. Annu Rev Biomed Eng 1: 241-263.
9. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD (1997) Neuropilin is a semaphorin III receptor. Cell 90: 753-762.
10. Li M, Yang H, Chai H, Fisher WE, Wang X, Brunicardi FC, Yao Q, Chen C (2004) Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer 101: 2341-2350.
11. Morelli MP, Calvo E, Ordonez E, Wick MJ, Viqueira BR, Lopez-Casas PP, Bruckheimer E, Calles-Blanco A, Sidransky D, Hidalgo M (2012) Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J Clin Oncol 30: e45-e48.
12. Müller MW, Giese NA, Swiercz JM, Ceyhan GO, Esposito I, Hinz U, Büchler P, Giese T, Büchler MW, Offermanns S, Friess H (2007) Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. Int J Cancer 121: 2421-2433.
13. Parikh AA, Liu WB, Fan F, Stoeltzing O, Reinmuth N, Bruns CJ, Bucana CD, Evans DB, Ellis LM (2003) Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 98: 720-729.
14. Poon RT, Fan ST, Wong J (2001) Clinical implications of circulating angiogenic growth factors in cancer patients. J Clin Oncol 19: 1207-1225.
15. Ruoslahti E, Bhatia SN, Sailor MJ (2010) Targeting of drugs and nanoparticles to tumors. J Cell Biol 188: 759-768.
16. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM Classification of Malignant Tumours. 7th edn. Wiley-Blackwell: Chichester, UK.
17. Soker S, Fidder H, Neufeld G, Klagsbrun M (1996) Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 27: 5761-5767.
18. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745.
19. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16: 510-520.
20. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E (2010) Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328: 1031-1035.
21. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (2009) C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 106: 16157-16162.
22. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3402-3408.
23. Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, Stoeltzing O, Somcio R, Liu W, Evans DB, Klagsbrun M, Gallick GE, Ellis LM (2005) Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer 93: 233-241.